PhEMI: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
(New page: {{PhEMI Top}} <font face="trebuchet ms" style="color:#000000">The Pharmacoepidemiology and Infectious Diseases (Pharmacoépidémiologie et Maladies Infectieuses–PhEMI) research group wa...)
 
No edit summary
 
(10 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{PhEMI Top}}
{{PhEMI top}}


<font face="trebuchet ms" style="color:#000000">The Pharmacoepidemiology and Infectious Diseases (Pharmacoépidémiologie et Maladies Infectieuses–PhEMI) research group was launched at the Institut Pasteur in 2007 as one of the teams of INSERM U657, subsequently becoming a separate Institut Pasteur unit in January 2008. Following an AERES evaluation (February 2009), a research team was also established at the University of Versailles Saint Quentin (UVSQ) in January 2010. The group became affiliated to INSERM again in January 2011. It is located on two different sites: the Institut Pasteur campus in Paris, and the UVSQ Medical School, Raymond Poincare University Hospital, Garches.
[[Image:Website_under_construction.png|750px]]
 
 
The Pharmacoepidemiology and Infectious Diseases (Pharmacoépidémiologie et Maladies Infectieuses–PhEMI) research group was launched at the Institut Pasteur in 2007 as one of the teams of INSERM U657, subsequently becoming a separate Institut Pasteur unit in January 2008. Following an AERES evaluation (February 2009), a research team was also established at the University of Versailles Saint Quentin (UVSQ) in January 2010. The group became affiliated to INSERM again in January 2011. It is located on two different sites: the Institut Pasteur campus in Paris, and the UVSQ Medical School, Raymond Poincare University Hospital, Garches.
   
   
Our research activities focus on the effects of population exposure to anti-infectious agents, in terms of the risks of infection, bacterial resistance to antibiotics and escape from vaccination, in particular. We investigate the interactions between human populations, antimicrobial drugs, and antimicrobial treatment escape by microbes at the population level, in both hospital and community settings. Our studies aim to evaluate the respective and combined impacts of cross-transmission, host-bacterium interaction (natural or induced by vaccination) and changes in the exposure of the population to antibiotics and vaccines.
Our research activities focus on the effects of population exposure to anti-infectious agents, in terms of the risks of infection, bacterial resistance to antibiotics and escape from vaccination, in particular. We investigate the interactions between human populations, antimicrobial drugs, and antimicrobial treatment escape by microbes at the population level, in both hospital and community settings. Our studies aim to evaluate the respective and combined impacts of cross-transmission, host-bacterium interaction (natural or induced by vaccination) and changes in the exposure of the population to antibiotics and vaccines.

Latest revision as of 07:43, 29 September 2014

Home        Research        Collaborate        Talks        Lab Members        Contact        Publications        Internal       



The Pharmacoepidemiology and Infectious Diseases (Pharmacoépidémiologie et Maladies Infectieuses–PhEMI) research group was launched at the Institut Pasteur in 2007 as one of the teams of INSERM U657, subsequently becoming a separate Institut Pasteur unit in January 2008. Following an AERES evaluation (February 2009), a research team was also established at the University of Versailles Saint Quentin (UVSQ) in January 2010. The group became affiliated to INSERM again in January 2011. It is located on two different sites: the Institut Pasteur campus in Paris, and the UVSQ Medical School, Raymond Poincare University Hospital, Garches.

Our research activities focus on the effects of population exposure to anti-infectious agents, in terms of the risks of infection, bacterial resistance to antibiotics and escape from vaccination, in particular. We investigate the interactions between human populations, antimicrobial drugs, and antimicrobial treatment escape by microbes at the population level, in both hospital and community settings. Our studies aim to evaluate the respective and combined impacts of cross-transmission, host-bacterium interaction (natural or induced by vaccination) and changes in the exposure of the population to antibiotics and vaccines.